AKT and cancer--is it all mTOR?
- PMID: 17045203
- DOI: 10.1016/j.ccr.2006.10.001
AKT and cancer--is it all mTOR?
Abstract
AKT, a key regulator of cell proliferation and survival, is commonly dysregulated in human cancers. Activated AKT kinase is oncogenic and required for tumorigenesis in PTEN-deficient animals. However, the importance of AKT in mediating transformation by other oncogenes and which of its targets are necessary for this process are poorly understood. In this issue of Cancer Cell, Skeen et al. show that AKT is required for transformation by mutant H-Ras and for experimental skin carcinogenesis. Moreover, the effects of AKT are mediated predominantly or solely via mTORC1. This suggests that AKT or mTOR inhibitors will be useful treatments for many cancers.
Comment on
-
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.Cancer Cell. 2006 Oct;10(4):269-80. doi: 10.1016/j.ccr.2006.08.022. Cancer Cell. 2006. PMID: 17045205
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
